Canaccord lowered the firm’s price target on Neurocrine (NBIX) to $158 from $163 and keeps a Buy rating on the shares. The firm called it a solid pick for these volitle times as the potential for upside is based on execution relative to its reset expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Strong Market Positioning and Growth Potential for Neurocrine’s Ingrezza Amidst Short-term Challenges
- Neurocrine announces publication of a post-hoc analysis of Ingrezza
- Optimistic Buy Rating for Neurocrine Due to Crenessity’s Potential in CAH Treatment
- Neurocrine price target lowered to $168 from $185 at H.C. Wainwright
- PepsiCo, Hormel, Neurocrine, Exelon, Aurora: Trending by Analysts